文献速递肿瘤 PET/CT放射性药物与辐射防护

[68Ga]Ga-FAPI-04 PET/CT用于IgG4相关疾病的亚型分型与预后评估

[68Ga]Ga-FAPI-04 PET/CT for subtyping and prognostication of IgG4-related disease.
PubMed 文献 · EJNMMI Res · 2026-05-13

该研究纳入68例IgG4相关疾病(IgG4-RD)患者,比较增殖型与纤维化型在[68Ga]Ga-FAPI-04 PET/CT上的纤维化活动差异。增殖型SUVmax、TBR、TLU和MLV均显著高于纤维化型;TBR≥16.3或SUVmean≥5的患者无复发生存期显著更短。

要点

  • 增殖型IgG4-RD的[68Ga]Ga-FAPI-04摄取显著高于纤维化型。
  • 胰腺-肝-胆疾病SUVmax和TBR最高,淋巴结最低。
  • TBR≥16.3或SUVmean≥5与更短无复发生存期相关。

核心结论

  • 增殖型IgG4-RD较纤维化型表现出更显著的[68Ga]Ga-FAPI-04摄取,提示更大的纤维化疾病负担。
  • [68Ga]Ga-FAPI-04 PET/CT衍生参数可预测IgG4-RD患者的无复发生存期。

研究设计与样本

  • 研究纳入68例IgG4-RD患者(增殖型50例,纤维化型18例;初诊未治疗47例,复发或持续性疾病21例),均行[68Ga]Ga-FAPI-04 PET/CT。
  • 在IgG4-RD病灶中测量SUVmax和靶本比(TBR),从MIM工作站获取代谢病灶体积(MLV)和总病灶摄取(TLU),并计算全局病灶SUVmean(TLU/MLV)。

主要发现

  • 增殖型较纤维化型SUVmax显著更高(16.59 ± 7.06 vs. 12.08 ± 4.65,P = 0.007),TBR亦显著更高(14.50 ± 7.98 vs. 10.32 ± 5.08,P = 0.036)。
  • 增殖型TLU和MLV均显著高于纤维化型(TLU中位数[IQR]:861.40 [340.40, 2465.48] vs. 419.15 [244.98, 657.90],P = 0.020;MLV:177.11 [79.99, 503.94] vs. 107.98 [54.10, 163.24],P = 0.029)。
  • 胰腺-肝-胆疾病SUVmax和TBR最高,其次为纤维化/主动脉周围炎、头颈部疾病和其他受累部位(P < 0.05);淋巴结SUVmax和TBR最低。
  • 增殖型与纤维化型患者无复发生存曲线无显著差异(P = 0.56)。
  • TBR ≥ 16.3或SUVmean ≥ 5的患者无复发生存期显著短于低于这些阈值的患者(TBR:39.7个月 vs. 未达到,P = 0.0078,风险比 = 5.74 [95%CI, 1.58-20.80];SUVmean:39.0个月 vs. 未达到,P = 0.019,风险比 = 4.36 [95%CI, 1.27-14.94])。

关键数值与推荐

  • IgG4-RD分为增殖型和纤维化型两个亚型。
  • TBR ≥ 16.3或SUVmean ≥ 5可作为无复发生存期的不良预后阈值。

临床怎么用

  • [68Ga]Ga-FAPI-04 PET/CT可用于区分IgG4-RD增殖型与纤维化型,并评估纤维化活动。
  • TBR和SUVmean等参数有助于识别复发风险较高的IgG4-RD患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recently, two subtypes of immunoglobulin G4-related disease (IgG4-RD), proliferative type and fibrotic type, were defined according to patients' clinicopathological characteristics. The objective of this study is to determine the difference of fibrotic activity shown in [68Ga]Ga-FAPI-04 PET/CT in these two subtypes of IgG4-RD. RESULTS: Sixty-eight IgG4-RD patients (50 proliferative subtype, 18 fibrotic subtype; 47 newly diagnosed treatment-naïve, 21 with relapsed or persistent disease after treatment) who underwent [68Ga]Ga-FAPI-04 PET/CT were enrolled. The SUVmax and target-to-background ratio (TBR) were measured in IgG4-RD lesions. Metabolic lesion volume (MLV) and total lesion uptake (TLU) were obtained from the MIM workstation, and SUVmean of the global lesions was calculated as the quotient of TLU and MLV (SUVmean = TLU/MLV). Proliferative subtype of IgG4-RD showed significantly higher uptake of [68Ga]Ga-FAPI-04 than the fibrotic subtype (SUVmax, 16.59 ± 7.06 vs. 12.08 ± 4.65, P = 0.007; TBR, 14.50 ± 7.98 vs. 10.32 ± 5.08, P = 0.036). The TLU and MLV were also significantly higher in the proliferative subtype (median [IQR], TLU, 861.40 [340.40, 2465.48] vs. 419.15 [244.98, 657.90], P = 0.020; MLV, 177.11 [79.99, 503.94] vs. 107.98 [54.10, 163.24], P = 0.029). The pancreato-hepato-biliary disease demonstrated the highest SUVmax and TBR, followed by fibrosis/periaortitis, head-and-neck disease, and others involvements (P < 0.05). Lymph nodes demonstrated the lowest SUVmax and TBR among all disease. The relapse-free survival curve did not show significant difference between proliferative and fibrotic patients (P = 0.56). Patients with TBR ≥ 16.3 or SUVmean ≥ 5 had significantly shorter relapse-free survival than those below these thresholds (TBR, 39.7 months vs. not reached, P = 0.0078, hazard ratio = 5.74 [95%CI, 1.58-20.80]; SUVmean, 39.0 months vs. not reached, P = 0.019, hazard ratio = 4.36 [95%CI, 1.27-14.94]). CONCLUSION: The proliferative subtype of IgG4-RD exhibited more dominant uptake of [68Ga]Ga-FAPI-04 than the fibrotic subtype, suggesting greater fibrotic disease burden. [68Ga]Ga-FAPI-04 PET/CT derived parameters is predictive of relapse-free survival in patients with IgG4-RD. TRIAL REGISTRATION: ClinicalTrials. NCT04125511 (Characterizing IgG4RD With 68GaFAPI PET/CT). Registered 14 October 2019, https//clinicaltrials.gov/study/NCT04125511?cond=NCT04125511&rank=1.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Liu S, Pan Q, Zhang H, et al. [68Ga]Ga-FAPI-04 PET/CT for subtyping and prognostication of IgG4-related disease. EJNMMI Res. 2026. PMID: 42129009. doi:10.1186/s13550-026-01451-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。